Tamara S. N.
- Country
- Spain
- Department
- Medical oncology
Research Overview
- Phase III Randomized Trial of AZD0901 with Capecitabine ± Rilvegostomig in First‑Line Claudin‑18.2‑Positive HER2‑Negative Advanced Gastric, GEJ or Esophageal Adenocarcinoma
- Efficacy and Safety of Zolbetuximab with Nab-Paclitaxel and Gemcitabine in Claudin 18.2 Positive Metastatic Pancreatic Adenocarcinoma
- Phase 3 Randomized Study of Trastuzumab Deruxtecan vs. Ramucirumab and Paclitaxel in HER2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Data & Insights
Has run more than one trial at 163 of 351 partner sites.
Specializations
Gastrointestinal Oncology
The investigator specializes in treating various forms of gastrointestinal cancers, with particular emphasis on gastric cancer and gastroesophageal junction adenocarcinoma. Their research encompasses both HER2-positive and CLDN18.2-positive disease variants.
- Advanced Gastric Cancer Treatment
- Gastroesophageal Junction Tumors
- Molecular Targeted Therapies
Hepatobiliary Medicine
The investigator focuses on treating complex biliary tract cancers and cholangiocarcinoma. Their expertise includes evaluating novel therapeutic approaches for patients with advanced disease stages, particularly those with specific genetic alterations like FGFR2 rearrangements.
- Advanced Biliary Tract Cancer
- Targeted Molecular Therapies
- Combination Treatment Strategies
Pancreatic Cancer Research
The investigator concentrates on advancing treatment options for pancreatic ductal adenocarcinoma, with specific interest in metastatic pancreatic cancer. Their work involves evaluating innovative combination therapies and targeted treatments for this aggressive disease.
- Metastatic Pancreatic Cancer
- Novel Therapeutic Combinations
- First-line Treatment Strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.